Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Artios Pharma Hooks Novartis & Pfizer In Over-Subscribed £65M Series B Round

Executive Summary

With DNA damage repair pathways attracting a lot of attention as potential targets against various cancers, three-year old Artios Pharma has raised £65 million in an over-subscribed Series B round to fund the clinical development of its pipeline through to 2023.
Advertisement

Related Content

Assessing Artios: $83m Series B, Big-Name Investors, Nothing In The Clinic
Finance Watch: Investments In Regenerative Therapies Surged In The Second Quarter
Artios Banks On DNA Repair To Challenge IO Space
A Whopper Of A Deal: AZ Hands Half Of Lynparza To Merck
Artios Launches With £25m To Study ‘PARP-esque’ DNA Damage Response Inhibitors

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123568

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel